SEC Form 4 · accession 0001190725-16-000359
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie A Donadio
Officer — Sr. VP, CFO
Period of report
Mar 21, 2016
Accepted (ET)
Mar 23, 2016 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $20.40 | Mar 21, 2016 | A | 1,250 | A | — | Mar 20, 2026 | Common Stock | 1,250 | 1,250 | D |
| Non-Qualified Stock Option (right to buy)F1 | $20.40 | Mar 21, 2016 | A | 18,750 | A | — | Mar 20, 2026 | Common Stock | 18,750 | 18,750 | D |
Explanation of responses
- F11/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.